RNA therapies such as oligonucleotides (OGNs) offer precision treatments for a variety of 31 neurological diseases, including epilepsy but their deployment is hampered by the blood brain 32 barrier (BBB). Here we used brain imaging and assays of serum proteins and tracer 33 extravasation, to determine that BBB disruption occurring after status epilepticus in mice was 34 sufficient to permit passage of systemically-injected antisense OGNs targeting microRNA-134 35 (Ant-134) into the brain parenchyma. A single intraperitoneal injection of Ant-134 two hours 36 after status epilepticus in mice resulted in potent suppression of spontaneous recurrent 37 seizures, reaching a 99.5% reduction during recordings at three months. The duration of 38 spontaneous seizures, when they occurred, was also reduced in Ant-134-treated mice. These 39 studies indicate that systemic delivery of Ant-134 reaches the brain and produces disease-40 modifying effects after systemic injection in mice when timed with BBB disruption and may be 41 a clinically-viable approach for this and other disease-modifying microRNA therapies. 42 43 44 45
48
Introduction 49 Targeting coding and noncoding RNAs offers unprecedented potential for precision 50 therapeutics and disease-modification (1). Among leading strategies is the use of antisense 51 oligonucleotides (OGNs) which are now approved for several neuromuscular diseases and in 52 clinical trials for other conditions (1, 2). There has been less progress, however, with 53 deployment of OGNs for the treatment of brain diseases. This is in part due to the blood brain 54 barrier (BBB) which prevents the passage of large macromolecules and small negatively 55 charged molecules from the systemic circulation into the brain (3). Overcoming the BBB may 56 be possible using encapsulation techniques or conjugation to cell-penetrant peptides, however 57 the safety and efficacy of these approaches remain uncertain. 58
Epilepsy is a common brain disease characterised by recurrent spontaneous seizures. 59
Many patients do not achieve seizure freedom with currently available anti-epileptic drugs and 60 there is an urgent and unmet need for disease-modifying or anti-epileptogenic therapies (4, 61 5). MicroRNAs (miRNAs) have recently emerged as a novel class of therapeutic target in 62 epilepsy (6). They are small noncoding RNAs that function post-transcriptionally to reduce 63 protein levels via base-pairing to complementary regions in target mRNAs. In the brain, 64 miRNAs are required for cell growth, differentiation and synaptic plasticity as well as the 65 control of neuroinflammation and apoptosis (7) . Notably, many of these processes are 66 dysregulated in epileptogenesis (6). Altered miRNA biogenesis has been detected in the 67 hippocampus of patients with epilepsy (8) and experimental deletion of certain miRNAs leads 68 to neurodegeneration and epilepsy in mice (9, 10). 69 Increased brain levels of miR-134-5p (MIR134; hereafter, miR-134) have been widely 70 reported in experimental and human temporal lobe epilepsy (11-13). miR-134 is a conserved, 71
brain-enriched miRNA that controls dendritic spine morphology via regulation of LIM kinase-1 72 (Limk1) (14), a well-characterized serine/threonine kinase that can regulate actin 73 polymerization, although other targets are known (15, 16) . Antagomirs are modified antisense 74
OGNs which produce potent and specific inhibition of miRNAs in vivo (1, 2, 17) . Previous 75 studies showed that reducing levels of miR-134 in the brain protects against evoked seizures 76 in multiple chemoconvulsant models (11) (12) (13) 18) . Moreover, intracerebroventricular (ICV) 77 injection of miR-134-targeting antagomirs after status epilepticus produced potent and lasting 78 reductions in the later occurrence of spontaneous recurrent seizures (SRS) in rats and mice 79 (11-13). The mechanism of action is uncertain although silencing miR-134 in vivo produces 80 dendritic spine phenotypes and rescue of protein levels consistent with a mechanism involving 81 de-repression of Limk1 (11, 18) . 82
As with other OGNs, studies tracking radiolabelled antagomirs have demonstrated they do 83 not reach the brain after systemic injection in healthy animals (19) . However, antagomirs 84 targeting miR-134 (Ant-134) might be used therapeutically after acute brain injuries or status 85 epilepticus. In this setting, there is likely to be a temporary disruption of BBB integrity (20) (21) (22) . 86
We hypothesized that we could deliver Ant-134 to a brain target (hippocampus) after systemic 87 administration if injected concurrent with BBB disruption. Here we tracked BBB disruption in a 88 mouse model of status epilepticus to inform the timing of systemic delivery of Ant-134. We 89 followed the effects on epilepsy and show potent and lasting suppression of seizure 90 activity and link the mechanism to de-repression of Limk1. 91 92 93
Results

94
Timing and size selectivity of BBB disruption following status epilepticus in mice 95
We first established the timing of BBB disruption after experimental status epilepticus and if it 96 is sufficient to allow passage of Ant-134 into the brain after systemic injection. Status 97 epilepticus was triggered by intraamygdala microinjection of kainic acid (KA) in mice, a well-98 characterised model of prolonged seizures that involves limbic networks and produces 99 damage to the ipsilateral hippocampus followed by the emergence of SRS within 3 -5 days 100 (23). The model has proved apt to study anti-epileptogenic therapies and was previously used 101
to study the effects of ICV-delivered Ant-134 on SRS in mice (11). Although studies have 102 suggested the model is associated with BBB disruption (24), the timing and size selectivity of 103 this disruption remains unknown. 104
We first confirmed macroscopic leakage of the BBB by intravenous (IV) injection of mice 105 with Evans Blue, an azo dye that has a high affinity for serum albumin, and visualising 106 extravasation at different time points (20). Whole and sectioned brains from these mice 107 displayed Evans Blue staining in multiple brain regions after status epilepticus including the 108 hippocampus ( Fig. 1A) . To support this finding, we used immunoblotting to assess the 109 extravasation of serum proteins into brain tissue. Hippocampal samples from saline-perfused 110 naïve mice or mice that received an intraamygdala injection of vehicle were largely devoid of To determine whether BBB disruption at two hours was sufficient to allow passage of a 117 macromolecule the size of Ant-134 (~6 kDa), we performed IV or intraperitoneal (IP) injections 118 of a fluorescein isothiocyanate (FITC)-conjugated 10 kDa dextran tracer 2 hours after status 119 epilepticus. Brain slices from mice were then analysed by fluorescence microscopy for 120 extravasation of FITC around cerebral microvessels. Both IV and IP injected FITC-dextran 121 was observed outside microvessels and within brain parenchyma in mice subject to status 122 epilepticus but not in vehicle-injected controls (Fig. 1E ). This included the ipsilateral 123 hippocampus, KA injection site and portions of the neocortex ( Fig. 1E and data not shown). 124
To extend these findings, we used live two-photon imaging through a cranial window to track 125 FITC-dextran (10 kDa) extravasation after IV injection around cerebral microvessels after 126 status epilepticus in living mice ( Fig. 1F; fig. S1C ). Beginning 1 hour after status epilepticus, 127
imaging confirmed FITC signal outside small vessels within the neocortex ipsilateral to the 128 side of seizure induction, which was not observed in non-seizure, vehicle-injected mice ( Fig.  129 1F). Limitations on imaging depth prevented analysis of the extravasation within the 130
hippocampus. 131
Finally, we imaged extravasation of magnetic resonance imaging (MRI) contrast agent (25) 132 in mice 2 hours after status epilepticus. Using 7-T scanning, we observed enhanced contrast 133 (manifested by an apparent signal disruption based on a T1 Flash MRI sequence) within the 134 seizure-damaged hippocampus after systemic gadolinium (Dg-DTPA-800 Da) injection ( Fig.  135 1G-H). While signal intensity returned to pre-gadolinium levels thereafter, this was delayed 136 on the ipsilateral relative to the contralateral side, reflecting leakage of the gadolinium into 137 surrounding brain tissue ( Fig. 1H ). Therefore, intraamygdala KA-induced status epilepticus in 138 mice leads to focal disruption of the BBB sufficient to allow passage of a systemically-injected 139 macromolecule such as an antagomir. 140 141
Systemic delivery of Ant-134 timed with BBB disruption blocks miR-134 upregulation 142
We used locked nucleic acid (LNA)-modified cholesterol-tagged antagomirs to achieve potent 143 and specific silencing of miR-134 (11). The targeting sequence and a 3D rendering of the 144 predicted structure of Ant-134 and Ant-134 bound to miR-134 are shown in Figs 2A-C. Two 145 hours after status epilepticus, mice were injected either IV or IP with 10 or 30 mg.kg -1 Ant-134, 146 with dosing guided by previous studies (17). Control mice were systemically injected with a 147 scrambled LNA-modified OGN (Scr). Brains were removed 24 hours later for analysis of miR-148 134 levels. 149 Hippocampal ( Fig. 2D ) and neocortical ( Fig. 2E ) levels of miR-134 were ~3 fold higher in 150 mice subject to status epilepticus compared to vehicle controls, consistent with previous 151 reports (11). IV and IP injection of either 10 or 30 mg.kg -1 Ant-134 blocked the upregulation of 152 miR-134 after status epilepticus ( Fig. 2D -E). We next measured levels of the miR-134 target 153
Limk1 in brain samples from the mice. Consistent with previous reports (11), protein levels of 154 Limk1 were lower in hippocampal samples from mice subject to status epilepticus, and this 155 was partly reversed in Ant-134-injected seizure mice ( Fig. 2F, G) . Notably, target de-156 repression was greatest in mice given 30 mg.kg -1 IP injection of Ant-134 ( Fig. 2F, G) . Based 157 on these findings and the less invasive delivery, an IP route was selected for studies 158 thereafter. Finally, to confirm that systemically delivered Ant-134 after status epilpeticus 159 reached the target tissue, we performed in situ hybridization (ISH) using specific probes for 160
Ant-134 on mouse brain tissue sections collected 24 hours after injection. ISH confirmed 161 strong Ant-134 staining within the ipsilateral hippocampus of mice that received an IP injection 162 of Ant-134 (30 mg.kg -1 ) 2 hours after status epilepticus (Fig. 2H ). The intensity of staining was 163 particularly notable around the CA3 subfield, which is the main lesion site and source of SRS 164 in the model (26). 165 166
Systemic Ant-134 produces potent and lasting suppression of epilepsy in mice 167
Next, we equipped mice with implantable EEG telemetry units to assess whether systemically-168 delivered Ant-134 affected epilepsy development. Animals were then subjected to status 169 epilepticus and, 2 hours later, given an IP injection of either 30 mg.kg -1 Ant-134 or Scr. 170
Because clinical trials do not use non-targeting OGNs as the placebo arm, we verified that the 171 basic epilepsy phenotype in Scr mice was similar to vehicle (saline) ( fig. S2A-B ). EEG 172 recording units were activated during status epilepticus and for the next 2 weeks. They were 173 then turned off and re-activated for one week of recording at 1, 2 and 3 months after status 174 epilepticus to assess the permanency of any effects, after which mice were killed and brains 175 processed for histology (see schematic in Fig. 3A) . 176
Systemic injection of Ant-134 did not alter epileptiform EEG parameters during the first 3 177 hours after status epilepticus, confirming the initial precipitating injury was equivalent between 178 groups that would be subsequently monitored ( Fig. 3B ). Seizure monitoring in freely-moving 179 Scr-treated mice during the first recording period determined that SRS emerged within 3 -4 180 days of status epilepticus, consistent with the known course of epilepsy in the model (11). 181 SRS occurred daily in most Scr mice, ranging from 1 -20 per day. In contrast, mice given a 182 systemic injection of Ant-134 after status epilepticus displayed only rare seizures during the 183 first two-week recording period and these emerged slightly later (at 5 -7 days) (see "Period 1" 184 from Fig. 3C and 3F; fig. S2C ). In the first 2 weeks of monitoring, we observed ~85% fewer 185 SRS in Ant-134-injected mice compared to controls ("Period 1", Table S1 ; fig. S2A ). A 186 secondary measure of seizure burden, based on the duration of seizures, revealed ~92% 187 reduction in Ant-134 injected mice when compared with Scr-injected mice ( fig. S2B ). 188
Ant-134-injected mice continued to display dramatically lower rates of SRS compared to 189 Scr mice during monitoring at 1, 2 and 3 months after status epilepticus (see "Periods 2, 3 and 190 4", respectively, Fig. 3C and 3F; fig. S2C ) and presented an overall average of 6.14 (out of 7) 191 days seizure-free (see "Periods 2 to 4", Table S1 ). Most notably, during the final week of 192 seizure monitoring, only a single SRS was detected in one of the Ant-134 mice compared to 193 an average of ~100 epileptic seizures in the Scr group ("Period 4", Table S1 ). This was 194 equivalent to a 99.5% lower seizure rate in Ant-134 mice in the third month, and around 93.4% 195 over all periods ( Fig. 3D ). On average, the duration of SRS was ~45% shorter in Ant-134-than 196
in Scr-injected mice over all monitoring periods ( Fig. 3E) . 
S3C). 208
We used additional brain tissue sections from the post-monitoring mice to stain for Ant-134. 209
The absence of the antagomir at the end of epilepsy monitoring would support a disease-210 modifying effect. Ant-134 staining was readily observed in positive control samples obtained 211 24 hours after status epilepticus from mice injected with Ant-134 whereas Ant-134 staining 212 was not detectable in the brain tissue sections from mice at the end of epilepsy monitoring 213 ( fig. S3D ). Therefore, the lack of SRS in Ant-134 mice was unlikely to be due to the continuing 214 presence of Ant-134 within the brain. 215 216 Anti-seizure mechanism of Ant-134 217
We next sought to explore the mechanism(s) by which Ant-134 produces anti-seizure effects. 218
Limk1 has a direct role in the control of dendritic structure and function function (14) and Ant-219 134 restores Limk1 levels after status epilepticus (11) (and see Fig. 2F -G). We therefore 220 hypothesised that the seizure-suppressive effects of Ant-134 may be due in part to de-221 repression of Limk1. Accordingly, lowering Limk1 levels should revert the anti-seizure 222 phenotype. To target Limk1, we used LNA-GapmeR OGNs (Gap-LIMK) which deplete target 223 mRNAs via an RNase H-dependent mechanism. We first performed in vitro screening to 224 identify an optimal sequence that reduced Limk1 levels by an amount equivalent to that found 225 to be recovered by Ant-134 treatment ( fig. S4A -C). The ability of an ICV injection of Gap-LIMK 226 to knockdown Limk1 was then confirmed in vivo (Fig. 5B ). Next, we equipped mice for EEG 227 telemetry recordings. One group of mice then received ICV injections of Gap-LIMK while the 228 other group received a scrambled (Scr) version and all mice were injected with Ant-134 (30 229 mg.kg -1 IP) 2 hours after status epilepticus. Gapmer injections were repeated every second 230 day. SRS frequency was quantified as before for a period of 2 weeks (see schematic in Fig.  231 5A). Note, injection of GAP-LIMK alone did not produce epilepsy in mice (data not shown). 232
As expected, the frequency of SRS was very low in mice given systemic Ant-134 after status 233 epilepticus and ICV injections of the non-targeting Gapmer ( Fig. 5C-D) . The frequency of SRS 234
in Ant-134-treated status epilepticus mice given Gap-LIMK was initially similar but within a few 235 days increased, reaching a frequency similar to the basic model (i.e. average of 4 -6 SRS per 236 day) ( Fig. 5C-D) . Thus, reducing Limk1 levels in vivo partly obviates the anti-seizure 237 phenotype of Ant-134, supporting de-repression of Limk1 in the anti-seizure mechanism of 238 Ant-134. 239
Based on these findings and the known multi-targeting effects of miRNAs, we sought to 240 identify other potential targets altered by Ant-134, performing transcriptional profiling of the 241 hippocampus of mice 24 hours after status epilepticus. This identified 16 differentially 242 expressed mRNAs between Scr and Ant-134-treated mice ( Figure 5E ). This suggests that the 243 downstream effects of Ant-134 at the transcriptome-level during epileptogenesis may be 244 subtle, complex, and/or time-sensitive. Nevertheless, significantly dysregulated mRNAs 245 included plausible candidate genes for an anti-seizure mechanism, including increased levels 246
of Kcnj10, an inward-rectifying potassium channel subunits, the loss of which may cause 247 epilepsy in humans (28). 248 249
Neuronal localisation of miR-134 in human pharmacoresistant epilepsy 250
Although previous studies reported that the level of miR-134 was increased in brain samples 251 from patients with pharmacoresistant temporal lobe epilepsy (11, 12), its cellular expression 252 in human brain is poorly understood. We therefore used ISH to identify the cell types 253 expressing miR-134 in human brain. Autopsy control and hippocampal tissue sections from 254 patients with pharmacoresistant temporal lobe epilepsy both displayed miR-134 staining and 255 this appeared exclusively neuronal ( Figure 6A and fig. S5A ). To confirm the cell phenotype 256 expressing miR-134 in human brain we performed fluorescence ISH using markers for 257 neurons (NeuN; Figure 6B ) and astrocytes (GFAP; fig. S5B ). This confirmed miR-134 is 258 restricted to neurons in the human hippocampus, suggesting neurons are a key target of Ant-259 134. 260
261
BBB impairment following seizures in humans 262
Human MRI studies using contrast agents have shown that epilepsy-causing brain injuries are 263 associated with temporal and anatomical BBB dysfunction (21), and BBB disruption can occur 264 after seizures (29). To provide a clinical context to our animal model findings, we analysed 265 contrast-enhanced MRI brain imaging studies of a set of three patients who recently Targeting miR-134 using OGNs has been particularly notable for the potency and disease-285 modifying actions demonstrated across different in vivo animal models (11-13, 18). Delivering 286
OGNs to the brain is a key challenge however, as is knowledge of the mechanism of action 287 because the multi-targeting actions of miRNAs raise unique safety concerns (6). Currently, 288
OGN delivery for brain diseases is expected to require an intrathecal or ICV route, or some 289 form of conjugation or encapsulation technique. However, BBB disruption accompanies many 290 epilepsy-triggering brain injuries (21), potentially facilitating non-invasive (i.e. systemic) 291 delivery. The present study addressed both delivery and mechanism of action, revealing that 292 systemic injection of Ant-134 can prevent SRS in experimental epilepsy, principally through a 293 single target. 294
While prolonged or repeated seizures are known to cause disruption of the BBB, the focus 295 until now has been on understanding how this contributes to epilepsy (20, 29). Here we asked 296 whether BBB disruption after status epilepticus could be appropriated to deliver a systemically-297 administered antagomir to treat epilepsy. Using multiple assessments of BBB integrity, 298
including extravasation of plasma markers and live brain imaging, we identified a disruption 2 299 hours after status epilepticus sufficient to allow passage of systemically administered Ant-134 300 into the brain parenchyma. While the upper size limit of this disruption was not pursued, the 301 selectivity size and timing align with earlier histological and biochemical findings in the same 302 model (24) and results in other models of status epilepticus (20). We focused on IV and IP 303 routes for delivering Ant-134 to the brain although other minimally invasive routes (e.g. Seizures were reduced by 99.5% during the final week of monitoring at three months. This 313 exceeds the performance of other anti-epileptogenic approaches currently under investigation 314 (5). The anti-seizure effect was also somewhat superior to the outcome when Ant-134 was 315 delivered by ICV route in the same model, perhaps due to differences in the amount of Ant-316 134 that reached brain sites (11, 13), including the contralateral hippocampus (23), or the 317 timing of Ant-134 delivery, which was slightly later in the present study (11, 13) . Appraisal of 318 how these individual variables affect performance may yield further improvements in 319 effectiveness. Further studies will be needed to determine if Ant-134 can prevent SRS 320 following epileptogenic insults besides status epilepticus (21, 22) . 321
The multi-targeting nature of miRNAs makes understanding the mechanism(s) by which 322 their inhibition produces anti-seizure effects uniquely challenging (30). Past studies showed 323 that miR-134 targets Limk1, a protein that promotes dendritic spine expansion by regulating 324 actin dynamics through phosphorylation of cofilin (14, 18). Here we used Gapmer OGNs to 325 produce a partial reduction in Limk1 levels, an approach that is physiologically relevant to the 326 scale of protein suppression by a miRNA on a target (7, 14) . This was sufficient to increase 327 SRS in Ant-134-treated epileptic mice, providing in vivo support for the disease-modifying 328 effects being a result of de-repression of Limk1. This implies the anti-seizure effects of Ant-329 134 result from adjustment to synaptic microstructure, perhaps curtailing the capacity of 330 neuronal networks to propagate hypersynchronous discharges (31). The finding fits with an 331 emerging view that some miRNAs produce strong effects on single targets, perhaps because 332 of spatial co-localisation (32). Notably, other anti-seizure antagomirs have been reported to 333 derive effects from de-repression of single ion channels (30). Nevertheless, Limk1 inhibition 334 did not fully obviate the anti-seizure effects of Ant-134 suggesting other targets of miR-134 335 may contribute to the observed phenotype or pathophysiology. On this note, we observed 336 reduced astrogliosis and sparing of interneurons in brain sections from Ant-134 mice, both of 337 which could account for reduced seizures (27, 33), but could also be a consequence of fewer 338 seizures. Our profiling of the hippocampal transcriptional landscape in Ant-134-treated mice 339 identified further potential targets that might be explored including potassium channels. 340
Studies in human cells or tissues will also be needed to assure clinical relevance of the Ant-341 134 mechanism and target pool. 342
The present findings improve the prospects for the development of an antagomir therapy 343 for epilepsy. An antagomir therapy has already completed clinical trials for hepatitis C (34), 344 various others are in development, and OGN-based treatments are in clinical use for 345 neuromuscular diseases (1). Although pK and toxicity studies have not yet been performed, 346 broad safety might be assumed on the basis that mice in our study were given a systemic 347 injection of Ant-134 and lived for three months. This may be helped by the largely CNS 348 expression of miR-134 (14), and we show here it is specifically expressed by neurons in the 349 human brain. While manipulation of a miRNA that regulates dendritic spines carries risks, Ant- 
Study design 379
Treatment (Ant-134) and control (Saline or Scramble) groups were randomly assigned before 380 the induction of status epilepticus, and the researcher was blind to the experimental groups 381 during injections. EEGs were randomly assigned for analysis, which was blindly performed by 382 two individuals. The sample size was defined based on previous work from our group(11), 
Seizure model and acute EEG assessments 405
Mice were anesthetized with isoflurane (isoflurane; 5% induction, 1-2% maintenance) and 406 placed in a mouse-adapted stereotaxic frame. Body temperature was maintained within the 407 normal physiological range with a feedback-controlled heat pad (Harvard Apparatus, Kent, 408 UK; Holliston, MA). For acute assessments (e.g. BBB study and molecular assessments after 409 Ant-134 injections), after making a midline scalp incision, the Bregma was located, and three 410 partial craniectomies were performed for the placement of skull-mounted recording screws 411 (Bilaney Consultants). A fourth craniectomy was drilled for the placement of a guide cannula 412 (coordinates from the Bregma: anterior-posterior (AP) = -0.94 mm, lateral (L) = -2.85 mm). 413
The cannula and electrode assembly was fixed in place with dental cement, and the mouse 414 was placed in a heated chamber for recovery prior to further studies. Mice were then placed 415 in an open Perspex box and connected to a Xltek® EEG brain monitor amplifier (Natus). After 416 baseline EEG was established, status epilepticus was triggered in freely-moving awake mice 417 by intraamygdala microinjection of KA (0.3 µg in 0.2 µl of PBS) (Sigma-Aldrich, Ireland), as 418 previously described (11). Control mice were injected with the same volume of PBS (pH 419 adjusted to 7.4). After 40 min, all mice, including controls, received lorazepam (8 mg/kg; 10 420 ml/kg; IP) to curtail seizures and reduce morbidity and mortality. Mice were recorded for 1-3 h 421 thereafter, according to experimental design, before being disconnected and placed in a 422 warmed recovery chamber. 423
Mouse EEG data were analyzed and quantified using LabChart 8 software (ADInstruments, 424
Oxford, U.K.). Seizures were defined as high-amplitude (> 2 x baseline) high-frequency (> 5 425 Hz) polyspike discharges lasting > 5 sec. Status epilepticus was defined as at least 5 min of 426 continuous seizure activity. From the EEG recordings we calculated the total power and % of 427 total power before lorazepam injection, as previously described (11). EEG total power was 428 plotted as percentage of baseline recording (each animal's EEG power post seizure compared 429 to its own baseline EEG). LNA-modified and 3′-cholesterol-modified oligonucleotides) in PBS (pH adjusted to 7.4) was 434 prepared in a sterile solution concentration of 7.5 mg.ml -1 , and injected IV or IP at 10 or 30 435 mg.kg -1 in mice at 2 h after intraamygdala KA-induced status epilepticus. 436 437
Long-term EEG telemetry recordings 438
Under isoflurane anaesthesia and using aseptic technique, mice were placed in a mouse-439 adapted stereotaxic frame. A mid-line incision was performed in the skin overlying the skull 440 and Bregma located. Four partial and one complete craniotomy was performed. The leads 441 from a DSI telemetry unit (Model: F20-EET, Data Systems International -DSI) were affixed to 442 the skull for bi-lateral EEG recordings (Ponemah v6.30 software, DSI) and the unit placed in 443 a subcutaneous pocket created in the upper back. A guide cannula was affixed (resting on the 444 dura mater) for the intraamygdala injection, as before. The electrode-cannula assembly was 445 fixed in place by dental cement and the mouse was removed from the stereotaxic frame and 446 allowed to recover. Mice were randomly and blindly assigned to experimental groups 447 (KA+Saline, KA+Scr or KA+Ant134), returned to home cages and provided with soft food and 448 fluids to aid recovery. Forty-eight hours later, EEG units were activated and a baseline 449 recording was obtained before triggering status epilepticus as above followed by lorazepam 450 after 40 min. Two hours later, mice were injected with saline, Scr or Ant-134 (30 mg.kg -1 ; IP; 451 10ml.kg -1 ). Continuous EEG data were then collected for 14 consecutive days (sampling 452 epoch called "Period 1"). Telemetry units were then turned off and only turned on exactly 1 453 month later for one week of continuous EEG recording (sampling epoch called "Period 2"; 454 days 30 th to 36 th after status epilepticus). Devices were deactivated again and re-activated at 455 2 and 3 months after status epilepticus (sampling epochs, respectively, "Period 3" / days 60 th 456 to 66 th ; and "Period 4" / days 90 th to 96 th ). At the end of the entire experiment, mice were deeply 457 anaesthetised and perfused with ice-cold saline and brains removed for 458 immunohistochemistry and in situ hybridization analysis. 459
Telemetry EEG data were reviewed and manually scored by an observer unaware of the 460 experimental treatment. The overall presence/number of spontaneous recurrent seizures 461 (SRS) per day of recording and the average seizure time were quantified. Seizure burden was 462 assessed only during "Period 1" to ensure statistical power was kept as initially planned. As 463 before, epileptic seizures were defined as high-frequency (>5 Hz), high-amplitude (>2× 464 baseline) polyspike discharges of ≥5 s duration. Quantified data was analysed as described 465 below (Statistical Analysis). 466 467
In vivo Limk1 silencing by GapmeRs 468
Mice were equipped with telemetry devices, as described before. Schematic for the 469 experimental design can be seen in Fig. 5B . Briefly, after a baseline EEG recording, mice 470 underwent intra-amygdala KA-induced SE, randomly/blindly assigned in groups, and 1h later 471 were intracerebroventricularly (ICV) injected with the first dose of GapmeR to silence Limk1 472 mRNA (called only "GapmeR"; n=4; 0.01 nmol/2µl) or its scramble negative control (called 473 "Scr"; n=3; 0.01 nmol/2µl). One more hour after the ICV injection (2h after SE), all mice were 474 systemically injected with Ant-134 (30 mg.kg -1 , IP). Long-term EEG was continued for 2 weeks, 475 and mice received ICV doses of GapmeR or Scr every 48h for the overall recording time (total 476 of seven administrations on experimental days 1, 3, 5, 7, 9, 11 and 13). EEG data were 477 
Qualitative BBB extravasation by Evans Blue 482
At 1 h, 2 h, 6 h and 16 h after status epilepticus, mice (n = 3 /group) were intravenously (IV) 483 injected with the azo dye 3% Evans Blue (5 ml/kg) to macroscopically and qualitatively assess 484 BBB disruption. Five minutes after dye injection, mice were deeply anesthetized 485 (pentobarbital) and transcardially perfused with ice-cold saline followed by 4% PFA, to clean 486 blood components and fix the tissue, respectively. Images were obtained using a 487 stereomicroscope from the whole brain and 1 mm coronal slices (dorsal and ventral 488 hippocampus). 489
490
FITC-dextran extravasation 491
After acute surgical/EEG procedures as before, mice were intravenously (IV; tail vein; 5 ml/kg) 492 or intraperitoneally (IP; 10 ml/kg) injected with the fluorescent reporter FITC-Dextran (10 kDa; 493 40 mg.kg -1 ) at 2 h after KA or PBS intraamygdala injection (n = 3/group). Five or 15 min after 494 dye injection (for IV and IP, respectively), mice were deeply anesthetized (pentobarbital) and 495 transcardially perfused with ice-cold saline followed by 4% PFA and whole brains snap frozen 496 and sectioned (40 µm; coronal; CM1900 cryostat, Leica). Slices were protected from light, 497 placed on a microscope slide and covered with a coverslip and qualitative assessed by 498 imaging using imaged using a Hamamatsu Orca 285 camera attached to a Nikon 2000s 499 epifluorescence microscope (Micron Optical). 500 501
Two-photon live imaging 502
For in vivo brain imaging, mice underwent a surgical procedure to create a cranial window. 503
Briefly, anaesthetised mice were placed in a stereotaxic frame with controlled body 504 temperature. The surgical procedure comprised of a 5 mm inner diameter craniotomy on the 505 skull surface (over the somatosensory area between the Bregma and lambda) of the mice 506 without disrupting the dura mater, and the placement of a clear sterile glass plate (fixed with 507 acrylic cement) to cover the cranial window. Mice were also implanted with a guide cannula 508 for intra-amygdala injection of PBS or KA prior to two photon imaging. After the procedure, 509 mice were allowed to recover in a heated chamber and returned to their cages for a week. On 510 the day of imaging, KA or PBS injection was performed as before. For imaging, the mouse 511 was placed on an imaging stage under 1-2% isoflurane anaesthesia and Immersol W was 512 placed between the W Plan-Apochromat 20x (NA 1.0) lens of the microscope and the window. 513
Imaging took place over 2 h. During this time body temperature was controlled and maintained 514 at 36.5-37.5 °C using a heating pad connected to a controller and eyes were covered with eye 515 protecting gel. After baseline images were captured, the fluorescent reporter FITC-Dextran 516 (10 kDa) was IV injected as above, 1 h after intraamygdala KA or PBS injection. The live 517 extravasation was recorded over time until the fluorescent reporter signal faded from vessels. 518
At 2 h after KA or PBS, mice were injected a second time with FITC-Dextran, as before, and 519 the cumulative extravasation observed. Z-stack images were acquired every 60s using an 520 upright Carl Zeiss LSM 710 NLO and Zen 2008. A Coherent Chameleon Vision II laser 521 operating at 780nm with 40.0% laser power (64 Mw at sample) and a 500-550nm emission 522 band pass filter was used for excitation and detection. After the procedure mice were 523 euthanized. Maximum projection images were prepared using FIJI (38) . 524 525 MRI in mice 526 BBB integrity was assessed 2 h following induction of status epilepticus (or intraamygdala 527 PBS injection, controls), using a dedicated small rodent 7-T MRI system 528 (www.neuroscience.tcd.ie/technologies/mri.php). Mice were anaesthetised with 5% isoflurane 529 and placed on an MRI-compatible support cradle with a built-in system for maintaining the 530 animal's body temperature at 37 °C and for physiological monitoring (ECG and respiration). A 531 cannula was flushed with saline and inserted into the tail vein. Accurate positioning was 532 ensured by acquiring an initial rapid pilot image, which was then used to ensure the correct 533 geometry for all subsequent scans. Compromises of the BBB were then visualised in high 534 resolution T1 weighted MR images (resolution, 0.156 X 0.156 X 5 mm 3 ; field of view: 20 X 20 535 X 17.9 mm 3 ; matrix; 128 X 128 X 30; TR/TE: 500/2.7 ms; flip angle: 30o; number of averages: 536 3; acquisition time: 2 min, 24 sec; Repetitions: 12) before and after tail-vein injection of 100 µl 537 of a 1 in 3 dilution of Gd-DTPA (0.5 M stock solution, Bayer). MRI analysis was performed 538 using ImageJ (Fiji), as described before (25) . The injection-to-MRI time intervals were ensured to be equal for both postictal and interictal 548 scans. Thus, each postictal qT1 volume could be contrasted with interictal qT1 volumes 549 acquired with the same injection-to-MRI time interval. The postictal enhancement of contrast 550 agent was quantified by subtracting postictal qT1 from interictal qT1 and the resulting ΔT1 was 551 used as a surrogate imaging marker of peri-ictal blood-brain barrier dysfunction. Seizure 552 duration, injection latency, and seizure type was determined retrospectively based on the 553 video-EEG-recordings (see legend to Fig. 6C for details) . The basic processing steps of the 554 qT1 data were performed using the FMRIB Software Library (FSL) and custom-built scripts 555 written in MATLAB (MathWorks®). The resulting volumes were processed using the standard 556 pipeline of the Freesurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/). Resulting 557 anatomical labels were extracted and ΔT1 values were averaged across the respective labels. 558
Additional peri-lesional labels were manually defined for patient #2. The average values of 559 labels were color-coded and colored labels were superimposed on the anatomical brain 560 volume. 561 562
Western blotting 563
Additional mice were used to assess the extravasation of albumin and IgG into the brain 564 parenchyma (24) or the effects of Ant-134 on Limk1 levels (11) after status epilepticus. Protein 565 was extracted from perfused brain samples, subjected to SDS-PAGE, transferred to 566 nitrocellulose membranes and incubated with primary antibodies to the following: Albumin 567
(1:1,000), Mouse IgG (1:2,000) (both from Cell Signaling Technology), Limk1 (1:1,000, 568 3842,from Cell Signaling Technology), β-actin (1:2,000, AC40, Sigma-Aldrich) and α-tubulin 569
(1:1,000, sc-8035, Santa Cruz Biotechnology). Membranes were then incubated with 570 horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch), and 571 bands were visualized using Supersignal West Pico Chemiluminescence Substrates (Pierce). 572
Images were captured using a Fuji-Film LAS-400, and densitometry was performed using 573
AlphaEaseFC4.0 gel-scanning integrated optical density software (Alpha Innotech). KA+Scr 574 IP and KA+Scr IV were grouped for statistical purposes (KA+Scr). Results are reported as 575 increased protein level (n fold change) in comparison to control samples. 576 577
Quantitative real-time PCR 578
Total RNA was isolated from ipsilateral cortex or hippocampus samples using Trizol 579 (Invitrogen), as described previously (11). For mRNA qPCR, 1 µg of total RNA was used to 580 generate complementary DNA (cDNA) by reverse transcription using SuperScript III reverse 581 transcriptase enzyme (Invitrogen) . Detection of Actin and Limk1 cDNA was performed by 582 SYBR-Green based quantitative Real-time PCR in 20 μL reaction on a Lightcycler 2.0 583
Carousel based system (Roche™). Reactions were incubated for 15 min at 95°C, followed by 584 50 cycles of 15 s at 94°C, 20 s at 55°C and 40 s at 72°C (annealing and extension) and then 585 15 s at 65° (melting). For each sample a Cycle Threshold (Ct) value was determined and then 586 a relative quantification following the ΔΔCt method was carried out using actin as reference 587 gene, all the values obtained was then normalized to the non-transfected samples. The 588
following primer pairs were used: Limk1: fwd 5'-TTATCGGGCGTGTGAATGCA-3'; rev 5'-589
ACCAGACAAGTGCATGCGAA-3';
House-keeping gene beta-actin: fwd 5'-590 TAGGCACCAGGGTGATG-3', rev 5'-GCCATGTTCAATGGGGTACT-3'. 591
For miRNA, 250 ng of RNA was reverse transcribed using stem-loop specific primers for 592 mmu-miR-134 and real-time quantitative PCR was carried out on a 7900HT Fast Realtime 593 System (Applied Biosystems) using TaqMan miRNA assays. Specific primers were purchased 594 from Sigma and were: RNU19 (Applied Biosystem miRNA assay ID 001186) and miR-134 595 (Applied Biosystem miRNA assay ID 000395). Expression of RNU19 was used for 596 normalization and relative fold change determined using the ΔΔ CT method (11). 597 598
In situ hybridization 599
Non-radioactive ISH was performed as described previously (11). For detection of Ant-134, 600 sections were prepared from mice killed 24 h or 3 months after status epilepticus. Ant-134-601 injected mice (n = 3/group) were transcardially perfused as before and either the whole brain 602 that all data associated with this study are available in the main text or the supplementary 849 materials. Experimental design for long-term epilepsy monitoring studies. After baseline (Bas.) EEG 918 recording, status epilepticus was induced then 2 hours later mice were injected with Ant-134 919 or Scr control (IP, 30 mg.kg -1 ) and followed for 14 days ("Period 1") and again for 7 days at 1 920 month ("Period 2"), 2 months ("Period 3") and 3 months ("Period 4"). 
